文献速递淋巴瘤

霍奇金淋巴瘤免疫检查点抑制剂治疗后的进展模式:对放射治疗的启示

Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy.
PubMed 文献 · Blood Adv · 2024-01-01

该研究纳入2013至2022年接受免疫检查点抑制剂(ICI)治疗的霍奇金淋巴瘤(HL)患者,回顾分析ICI前及进展时的FDG-PET。69例可评估患者中,41例进展,其中22例仅在原病灶部位进展;ICI前≤5个病灶(局限期)患者中,可治疗性进展的累积发生率为34%。超过三分之一的局限期患者仅在原部位进展,可能适合在ICI治疗期间或之后接受放疗。

要点

  • 69例HL患者中,41例在ICI治疗中或治疗后进展,累积发生率为66.4%。
  • 22例仅在原病灶部位进展,累积发生率为39.4%。
  • ICI前≤5个病灶的45例患者中,可治疗性进展的累积发生率为34%。

核心结论

  • 超过三分之一的ICI前局限期HL患者仅在原病灶部位进展,这些患者可能适合在ICI治疗期间或之后接受放疗。

研究设计与样本

  • 回顾性研究,纳入2013年至2022年接受ICI治疗的HL患者,共识别90例,其中69例有病历记录。
  • 32例(52%)在开始ICI时为复发,17例(25%)为难治,16例(23%)接受ICI一线治疗。
  • 45例(69例中)在ICI前FDG-PET上有≤5个病灶(局限期)。

主要发现

  • 中位随访4.0年,69例中41例在ICI治疗中或治疗后进展,累积发生率为66.4%。
  • 41例进展患者中,22例仅在原病灶部位进展,累积发生率为39.4%。
  • ICI前>5个病灶的患者进展风险更高,每多一个超过5个的病灶,进展风险增加1.2倍。
  • 探索性分析中,45例局限期患者可治疗性进展的累积发生率为34%。
  • 该队列任何进展的累积发生率为58.9%。

临床怎么用

  • 作者认为,ICI前局限期且在ICI治疗期间或之后仅在原病灶部位进展的患者,可能适合接受放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress. Patterns of progression after ICIs are not well described and are essential to defining the role of local therapies in combination with ICIs. We identified patients who received ICIs for HL between 2013 and 2022. Fludeoxyglucose-18 positron emission tomography (FDG-PET) before initiating ICI and at progression on/after ICI were reviewed, and areas of active HL were recorded. An exploratory analysis of treatable progression included patients with ≤5 sites of disease on pre-ICI FDG-PET and progression only at pre-ICI sites. Ninety patients were identified; 69 had complete records, and of these, 32 (52%) had relapsed at ICI initiation, 17 (25%) were refractory, and 16 (23%) received ICI as first-line therapy. Forty-five of 69 patients had ≤5 sites of disease (limited) on pre-ICI FDG-PET. Patients with >5 sites of disease had a higher risk of progression, and every site of disease >5 sites conferred an additional 1.2x higher chance of progression. At a median follow-up of 4.0 years, 41 of 69 patients had progressed on/after ICIs (cumulative incidence 66.4%), and of these, 22 of 41 patients progressed only at pre-ICI sites (cumulative incidence 39.4%). In an exploratory analysis, the cumulative incidence of a treatable progression among 45 patients with limited disease was 34%. The cumulative incidence of any progression among this cohort was 58.9%. More than one-third of patients with limited disease before ICIs experienced progression only at pre-ICI sites of disease. These patients could be candidates for radiation during or after ICIs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Burlile JF, Frechette KM, Breen WG, et al. Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy. Blood Adv. 2024. PMID: 38206755. doi:10.1182/bloodadvances.2023011533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。